TCGA-A7-A4SE-01A-11R-A266-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- ANGIOGENESIS+0.420
- HEDGEHOG_SIGNALING+0.380
- TNFA_SIGNALING_VIA_NFKB+0.370
- APICAL_JUNCTION+0.350
- G2M_CHECKPOINT+0.350
- E2F_TARGETS+0.340
- INTERFERON_ALPHA_RESPONSE+0.340
- NOTCH_SIGNALING+0.340
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- PROTEIN_SECRETION-0.430
- PEROXISOME-0.390
- FATTY_ACID_METABOLISM-0.380
- ESTROGEN_RESPONSE_EARLY-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- ADIPOGENESIS-0.320
- ESTROGEN_RESPONSE_LATE-0.280
- BILE_ACID_METABOLISM-0.210
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 218cda38-ec89-4e23-849b-93f1b5bd0655 | — | — | 0.838 |
| 2 | 20020022.TNBC | — | D | 0.835 |
| 3 | TCGA-B6-A400-01A-11R-A239-07 | — | E | 0.828 |
| 4 | 20050166.TNBC | — | D | 0.816 |
| 5 | TCGA-A2-A3XY-01A-11R-A239-07 | — | D | 0.807 |
| 6 | 20030032.TNBC | — | D | 0.807 |
| 7 | DRR168520 | — | — | 0.790 |
| 8 | SRR8613770 | — | E | 0.787 |
| 9 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.785 |
| 10 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |